# Atopic dermatitis monoclonal antibody clinical developments > Live situation record from CLSTR: https://clstr.news/situations/atopic-dermatitis-monoclonal-antibody-clinical-developments > Updated: 2026-10-18T19:41:38.000Z. Sources: 2. Developments: 2. Clinical data released in October 2026 highlights long-term efficacy for monoclonal antibody treatments targeting atopic dermatitis and prurigo nodularis. Initial findings from the ARCADIA and OLYMPIA studies showed that nemolizumab, which inhibits interleukin-31 (IL-31) signaling, maintained skin clearance and itch relief for up to three years. In the ARCADIA study, 80% of early responders achieved an EASI-90 score by week 152, while the OLYMPIA study reported that over 85% of patients with prurigo nodularis experienced clinically meaningful itch improvement. Subsequent reports expanded on these advancements, including Phase 2 data showing nemolizumab provided lasting improvements in itch, sleep, and quality of life for children aged 2 to 11. Additionally, 5-year data for lebrikizumab was presented, demonstrating sustained skin clearance and itch control in adults and adolescents, with 92.9% of subjects achieving EASI-75 at the 108-week mark. ## Timeline ### 2026-10-18: Atopic dermatitis treatments show long-term efficacy in new clinical data Clinical studies show promising long-term results for nemolizumab in children and lebrikizumab in adults treating moderate-to-severe atopic dermatitis. 2 sources. https://clstr.news/cluster/atopic-dermatitis-treatments-show-long-term-efficacy-in-new-clinical-data ### 2026-10-10: Nemolizumab shows sustained skin and itch relief for up to 3 years Long-term data shows nemolizumab provides sustained skin clearance and itch relief for up to three years in patients with atopic dermatitis and prurigo nodularis. 2 sources. https://clstr.news/cluster/nemolizumab-shows-sustained-skin-and-itch-relief-for-up-to-3-years --- Cite as: Atopic dermatitis monoclonal antibody clinical developments. CLSTR, https://clstr.news/situations/atopic-dermatitis-monoclonal-antibody-clinical-developments